[ij] [ij] [ij] 
Email id

Research Journal of Pharmacy and Technology
Year : 2019, Volume : 12, Issue : 6
First page : ( 3098) Last page : ( 3104)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2019.00524.9

Translational Chemotherapy for triple negative Breast Cancer-A Review on significance of poly (ADP-ribose) polymerase 1 (PARP 1) inhibitors

Eldhose Elizabeth1, Gowramma B.1,*, Mohammed Manal2, Kalirajan R.1, Kaviarasan L.1

1Department of Pharmaceutical Chemistry, JSS College of Pharmacy, Udhagamandalam, Tamilnadu

2Department of Pharmaceutical Chemistry, KTN College of Pharmacy, Kerala

*Corresponding Author E-mail: gowrammab@rediffmail.com, gowrammab@jssuni.edu.in

Online published on 8 August, 2019.


Breast Cancer, the most common cancer observed in women around the world[1], accounts for 12% of all new cancer cases and nearly 25% of all cancers in women[2]. Breast Cancer, a heterogenous disease, is evident over a broad differentiation in phenotypes and morphological profiles, with an after effect of various clinical behaviours[3]. From an estimated 1 million breast cancer cases diagnosed worldwide, 170, 000 are of triple negative phenotype (15–20%)[4]. Triple Negative Breast Cancer (TNBC) is a substantially histopathological category based, where there is deficiency of expression of hormone receptors (ER and PR) as well as no transmutation of human epidermal growth factor receptor type 2 (HER2)[3]. They are characterized by poor prognosis and aggressiveness construed by low five-year survival and high recurrence rates after adjuvant therapy. TNBC share arresting correlation with basal-like breast cancers. It is observed with high frequency of BRCA1 mutations and a heightened Ki-67 expression. Taxanes and/or platinum compounds and PARP 1 inhibitors are a good choice of treatment for TNBC[4]. The intent of this review is to highlight the relevance of PARP 1 inhibitors on TNBC and display an in depth discussion regarding these futuristic inhibitors.



Breast Cancer, Triple Negative Breast Cancer, Human Epidermal Growth Factor Receptor, Taxanes, Poly (ADP-ribose) polymerase 1 Inhibitor.


║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
738,940,615 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.